CD8A and type 1 diabetes mellitus: The lipid surface exhibits the antigen protein and a ligand of the B cell inhibitory co-receptor CD22, which work synergistically to prevent B cells from getting activated upon identifying the antigen.8 The optimal treatment for type 1 diabetes (T1D) is the recovery of immunological tolerance to cellular antigens since T1D is induced by the death of pancreatic beta cells by autoantigen-selective immunity CD4+ and CD8+ T lymphocytes.